Close

Exelixis (EXEL) Says EMA Accepts MAA for Cabozantinib as Treatment for Advanced Renal Cell Carcinoma

January 28, 2016 4:10 PM EST Send to a Friend
Exelixis, Inc. (NASDAQ: EXEL) today announced the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login